Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures (Q34845773)

4 August 2017

0 references

Summary of meta-analyses of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures (English)

1 reference

postmenopausal osteoporosis

4 August 2017

0 references

0 references

1 reference

1 reference

1

Gordon H Guyatt

1 reference

4 August 2017

Ann Cranney

2

1 reference

4 August 2017

Lauren Griffith

3

1 reference

4 August 2017

Stephen Walter

4

1 reference

4 August 2017

Nicole Krolicki

5

1 reference

4 August 2017

Murray Favus

6

1 reference

4 August 2017

Clifford Rosen

7

1 reference

4 August 2017

language of work or name

1 reference

1 September 2002

1 reference

Endocrinology and Metabolism Clinics of North America

4 August 2017

published in

1 reference

4 August 2017

volume

31

1 reference

4 August 2017

issue

3

1 reference

4 August 2017

page(s)

659-79, xii

1 reference

Risk of Mortality Following Clinical Fractures

4 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Risk of new vertebral fracture in the year following a fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Vertebral fractures and mortality in older women: a prospective study. Study of Osteoporotic Fractures Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

A meta-analysis of etidronate for the treatment of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Fluoride for the treatment of postmenopausal osteoporotic fractures: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Bias in treatment assignment in controlled clinical trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Physician interpretations and textbook definitions of blinding terminology in randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Which fractures are associated with low appendicular bone mass in elderly women? The Study of Osteoporotic Fractures Research Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Antifracture efficacy of antiresorptive agents are related to changes in bone density.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

A method to assess the proportion of treatment effect explained by a surrogate endpoint

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8529%2802%2900024-5

7 January 2021

10.1016/S0889-8529(02)00024-5

Identifiers

DOI

1 reference

4 August 2017

1 reference